Gufic Biosciences Limited (GUFICBIO.BO)
INR 317.25
(2.11%)
INR 317.25
(2.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 861.35 Million INR | 8.07% |
| 2022 | 797.04 Million INR | -16.84% |
| 2021 | 958.4 Million INR | 116.68% |
| 2020 | 442.31 Million INR | 94.96% |
| 2019 | 226.87 Million INR | 3.41% |
| 2018 | 219.4 Million INR | 33.17% |
| 2017 | 164.76 Million INR | 82.65% |
| 2016 | 90.2 Million INR | 23.16% |
| 2015 | 73.24 Million INR | 76.17% |
| 2014 | 41.57 Million INR | -2.5% |
| 2013 | 42.64 Million INR | 28.09% |
| 2012 | 33.29 Million INR | 118.01% |
| 2011 | 15.27 Million INR | 4.31% |
| 2010 | 14.64 Million INR | 19.24% |
| 2009 | 12.27 Million INR | 46.8% |
| 2008 | 8.36 Million INR | -4.64% |
| 2007 | 8.77 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 208.56 Million INR | 4.04% |
| 2023 Q3 | 222.57 Million INR | -4.1% |
| 2023 Q4 | 200.45 Million INR | -9.93% |
| 2023 FY | 861.35 Million INR | 8.07% |
| 2023 Q2 | 232.09 Million INR | 12.54% |
| 2023 Q1 | 206.22 Million INR | 13.9% |
| 2022 FY | 797.04 Million INR | -16.84% |
| 2022 Q3 | 203.36 Million INR | 0.62% |
| 2022 Q4 | 181.05 Million INR | -10.97% |
| 2022 Q1 | 210.51 Million INR | 3.89% |
| 2022 Q2 | 202.11 Million INR | -3.99% |
| 2021 Q3 | 210.32 Million INR | -9.87% |
| 2021 Q4 | 202.64 Million INR | -3.65% |
| 2021 Q1 | 312.07 Million INR | 68.99% |
| 2021 FY | 958.4 Million INR | 116.68% |
| 2021 Q2 | 233.36 Million INR | -25.22% |
| 2020 FY | 442.31 Million INR | 94.96% |
| 2020 Q4 | 184.67 Million INR | 19.41% |
| 2020 Q3 | 154.64 Million INR | -10.76% |
| 2020 Q2 | 173.29 Million INR | 1309.23% |
| 2020 Q1 | -14.33 Million INR | -130.34% |
| 2019 Q4 | 47.22 Million INR | -32.72% |
| 2019 Q3 | 70.19 Million INR | 63.11% |
| 2019 Q2 | 43.03 Million INR | -36.81% |
| 2019 Q1 | 68.1 Million INR | 10.14% |
| 2019 FY | 226.87 Million INR | 3.41% |
| 2018 Q3 | 58.8 Million INR | -4.96% |
| 2018 FY | 219.4 Million INR | 33.17% |
| 2018 Q4 | 61.84 Million INR | 5.17% |
| 2018 Q2 | 61.87 Million INR | 2.87% |
| 2018 Q1 | 60.14 Million INR | 99.78% |
| 2017 Q1 | 35.41 Million INR | 341.55% |
| 2017 FY | 164.76 Million INR | 82.65% |
| 2017 Q3 | 62.92 Million INR | 13.19% |
| 2017 Q4 | 30.1 Million INR | -52.16% |
| 2017 Q2 | 55.59 Million INR | 56.99% |
| 2016 FY | 90.2 Million INR | 23.16% |
| 2016 Q2 | 26.52 Million INR | 3.52% |
| 2016 Q1 | 25.62 Million INR | 15.65% |
| 2016 Q4 | 8.02 Million INR | -74.35% |
| 2016 Q3 | 31.26 Million INR | 17.88% |
| 2015 Q1 | 10.4 Million INR | -5.63% |
| 2015 Q2 | 16.5 Million INR | 58.69% |
| 2015 Q3 | 24.17 Million INR | 46.45% |
| 2015 FY | 73.24 Million INR | 76.17% |
| 2015 Q4 | 22.15 Million INR | -8.37% |
| 2014 Q3 | 6.76 Million INR | -42.89% |
| 2014 Q4 | 11.02 Million INR | 62.93% |
| 2014 Q2 | 11.84 Million INR | -0.75% |
| 2014 Q1 | 11.93 Million INR | -4.88% |
| 2014 FY | 41.57 Million INR | -2.5% |
| 2013 Q2 | 11.47 Million INR | 44.2% |
| 2013 Q4 | 12.55 Million INR | 17.7% |
| 2013 FY | 42.64 Million INR | 28.09% |
| 2013 Q3 | 10.66 Million INR | -7.07% |
| 2013 Q1 | 7.95 Million INR | 11.47% |
| 2012 FY | 33.29 Million INR | 118.01% |
| 2012 Q1 | 8.75 Million INR | 792.86% |
| 2012 Q4 | 7.13 Million INR | -16.11% |
| 2012 Q3 | 8.5 Million INR | -4.24% |
| 2012 Q2 | 8.88 Million INR | 1.45% |
| 2011 Q3 | 3.86 Million INR | 0.0% |
| 2011 FY | 15.27 Million INR | 4.31% |
| 2011 Q4 | 981 Thousand INR | -74.62% |
| 2010 FY | 14.64 Million INR | 19.24% |
| 2009 FY | 12.27 Million INR | 46.8% |
| 2008 FY | 8.36 Million INR | -4.64% |
| 2007 FY | 8.77 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 86.013% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 97.285% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 81.708% |
| Granules India Limited | 4.05 Billion INR | 78.748% |
| Indoco Remedies Limited | 984.6 Million INR | 12.517% |
| Achyut Healthcare Limited | 5.73 Million INR | -14927.146% |
| Ajanta Pharma Limited | 8.16 Billion INR | 89.446% |
| Alkem Laboratories Limited | 17.95 Billion INR | 95.203% |
| Alpa Laboratories Limited | 167.76 Million INR | -413.43% |
| Brooks Laboratories Limited | -195.91 Million INR | 539.649% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 46.669% |
| Bajaj HealthCare Limited | -837.93 Million INR | 202.796% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -14.156% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 98.453% |
| Eris Lifesciences Limited | 3.91 Billion INR | 78.026% |
| FDC Limited | 3.05 Billion INR | 71.779% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 105.736% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 79.538% |
| Ipca Laboratories Limited | 5.47 Billion INR | 84.263% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -283.455% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 536.607% |
| Lasa Supergenerics Limited | -217.3 Million INR | 496.379% |
| Laurus Labs Limited | 1.6 Billion INR | 46.35% |
| Lupin Limited | 19.14 Billion INR | 95.501% |
| Mankind Pharma Limited | 19.12 Billion INR | 95.497% |
| Medicamen Biotech Limited | 109.31 Million INR | -687.994% |
| Medico Remedies Limited | 82.9 Million INR | -938.917% |
| Megasoft Limited | -127.46 Million INR | 775.754% |
| NATCO Pharma Limited | 13.88 Billion INR | 93.796% |
| Piramal Pharma Limited | 178.2 Million INR | -383.365% |
| RPG Life Sciences Limited | 876.6 Million INR | 1.739% |
| Sigachi Industries Limited | 571.8 Million INR | -50.639% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.101% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 71.315% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -240.266% |
| Unichem Laboratories Limited | -704.74 Million INR | 222.223% |
| Wanbury Limited | 559.56 Million INR | -53.934% |
| Windlas Biotech Limited | 581.87 Million INR | -48.032% |
| ZIM Laboratories Limited | 172.46 Million INR | -399.441% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 97.768% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 122.245% |
| Divi's Laboratories Limited | 16 Billion INR | 94.617% |
| Hester Biosciences Limited | 188.89 Million INR | -356.009% |
| Procter & Gamble Health Limited | 2 Billion INR | 57.142% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -91.529% |
| Bal Pharma Limited | 73.92 Million INR | -1065.223% |
| Strides Pharma Science Limited | -706.14 Million INR | 221.981% |
| Venus Remedies Limited | 284.9 Million INR | -202.328% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 60.288% |
| Nectar Lifesciences Limited | 49.95 Million INR | -1624.436% |
| Shilpa Medicare Limited | 318.74 Million INR | -170.236% |
| Aarti Drugs Limited | 1.71 Billion INR | 49.751% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 35.925% |
| Suven Life Sciences Limited | -1.05 Billion INR | 181.974% |
| Ind-Swift Limited | 142.31 Million INR | -505.255% |
| Valiant Laboratories Limited | 3.19 Million INR | -26851.064% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 84.413% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 115.181% |
| Themis Medicare Limited | 435.23 Million INR | -97.905% |
| Hikal Limited | 696.02 Million INR | -23.754% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 94.8% |
| Sequent Scientific Limited | -358.69 Million INR | 340.139% |
| Novartis India Limited | 851.9 Million INR | -1.11% |
| Wockhardt Limited | -4.63 Billion INR | 118.604% |
| Jubilant Pharmova Limited | 771 Million INR | -11.719% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -12045.46% |
| Neuland Laboratories Limited | 3 Billion INR | 71.296% |
| Morepen Laboratories Limited | 961.59 Million INR | 10.425% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -489.913% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1049.498% |